SEC Filing · F-4/A
Oncolytics Biotech, Inc.
ONCYNASDAQEQUITYCurrent
SEC Filing
Company context
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically “cold” tumors “hot” through the activation of innate and adaptive immune responses.
Current securities
As-filed source
As filedOpen full document ↗